by Eric Christianson | Nov 22, 2020 | Clinical Pharmacy News and New Drug Updates
Working with geriatric patients and providers in primary care, I definitely have to stay up to date with regards to diabetes therapy. There have been a couple of diabetes updates in 2020 that I wanted to make sure you were aware of. The SGLT2 inhibitors is a class of...
by Eric Christianson | Sep 16, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
GLP-1 agonists are an effective medication in treating type 2 diabetes mellitus. GLP-1 agonists are a synthetic version of the body’s naturally occurring GLP-1. However, synthetic GLP-1 has the advantage of being resistant to DPP4 degradation. GLP-1 agonists have...
by Eric Christianson | Jul 26, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Glucagon-like peptide-1 receptor agonists, or GLP-1s, are a highly appealing, newer class of medications for the treatment of type 2 diabetes. Through their activity at the GLP-1 receptor, they slow gastric emptying and decrease glucagon secretion. They also increase...
by Eric Christianson | Jul 12, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Sodium-glucose co-transporter 2 inhibitors (SGLT2s) are becoming popular treatments for type 2 diabetes mellitus. While typically classified as diabetes medications, there is more and more research coming out for their benefits in cardiovascular health and heart...
by Eric Christianson | Feb 19, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
A compelling indication is simply another reason (typically a disease state) as to why you choose a medication. Compelling indications in diabetes are increasingly important in medication selection in diabetes. I lay out some of those reasons below. Metformin...
